Literature DB >> 14747600

Prophylactic aspirin use in the adult general population.

P Trinder1, G Rajaratnam, M Lewis, P Croft.   

Abstract

BACKGROUND: The aim of the study was to establish the prevalence and patterns of aspirin use in people with vascular problems.
METHODS: A cross-sectional population survey was carried out on a stratified random sample of 10,000 adults aged 35 and over in North Staffordshire.
RESULTS: A total of 6322 adults replied to the questionnaire (adjusted response 67 percent). The prevalence of vascular problems was 12.9 percent, and 67.6 per cent of respondents were using aspirin. The main association with aspirin use was previous advice about aspirin: adults who recalled being given advice were more likely to be using aspirin. Increasing age, disease severity and level of deprivation were also associated with increased aspirin use. Of adults without vascular problems, 7.1 percent also reported using aspirin regularly.
CONCLUSIONS: There is still potential to increase aspirin use in those with vascular problems. The extent and quality of health care professionals' advice may be an important area to target. The reasons why some people without vascular problems take regular aspirin is an area for further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14747600     DOI: 10.1093/pubmed/fdg079

Source DB:  PubMed          Journal:  J Public Health Med        ISSN: 0957-4832


  3 in total

Review 1.  Improving the gastrointestinal tolerability of aspirin in older people.

Authors:  Julia L Newton
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

2.  The role of aspirin in post-polypectomy bleeding--a retrospective survey.

Authors:  Antony Pan; Martin Schlup; Ralf Lubcke; Annie Chou; Michael Schultz
Journal:  BMC Gastroenterol       Date:  2012-10-10       Impact factor: 3.067

Review 3.  Factors associated with self-care activities among adults in the United Kingdom: a systematic review.

Authors:  Angela Ryan; Sue Wilson; Aliki Taylor; Sheila Greenfield
Journal:  BMC Public Health       Date:  2009-04-05       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.